About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 10.62%, which has investors questioning if this is right time to ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

Rakuten Medical initiates global phase 3 trial of ASP-1929 photoimmunotherapy in combo with pembrolizumab to treat recurrent head and neck cancer: United States Saturday, January ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...